Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial

Trial Profile

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 19 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
    • 29 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2015, as reported by ClinicalTrials.gov record.
    • 09 Sep 2015 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top